Pang Yong Kek Malaysia

Associate Prof Pang Yong Kek is currently practising at Universiti Malaya Specialist Centre as a respiratory consultant. He was reappointed as an adjunct professor at Universiti Malaya after his retirement this year. His research interests are diverse, and he is committed to Continuous Medical Education. To date, he has been invited to speak at various scientific events, both locally and overseas. Additionally, he is active in several professional societies, including the Malaysian Thoracic Society, where he served as immediate past president. He is also a board member of the Lung Foundation of Malaysia.
Job Title
Consultant Respiratory Physician
Faculty / Department / Division
Faculty of Medicine/Department of Medicine/Division of Respiratory Medicine
Institution / Organisation
University Malaya

20 November 2026, Friday

Time Session
09:30
11:00
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
  • David Halpin Speaker United Kingdom
  • Antonio Anzueto Speaker United States
  • Wisia Wedzicha Speaker United Kingdom
    This presentation will review aspects of COPD exacerbation management in the GOLD 2027 report.
  • Pang Yong Kek Speaker Malaysia
    Title: Leveraging Digital Tools in COPD Management for 2027 & Beyond Routine outpatient management of COPD faces a double deficit: up to 70% of patients make critical inhaler errors, with real-world adherence below 50%, whilst fewer than 3% complete centre-based pulmonary rehabilitation (PR). Digital healthcare addresses this through two synergistic pillars: connected smart inhalers—which enhance adherence by 22%–35% and reduce exacerbations by 17%–30% via objective flow and technique tracking—and digital therapeutics like myCOPD and Kaia COPD, which improve exercise capacity (+57.68 m 6MWD) with outcomes non-inferior to in-person PR. Remote Therapeutic Monitoring (RTM) billing frameworks establish clinical and financial viability by reimbursing multidisciplinary management of non-physiological data, medication adherence, and patient-reported outcomes. Looking toward 2027, multi-modal data fusion—integrating wearable vitals, acoustic cough biomarkers, and smart inhaler actuations—enables machine learning algorithms to forecast acute exacerbations up to 7 days ahead with 92% accuracy, aligning with recent GOLD strategy updates on early phenotypes (Pre-COPD/PRISm) and AI integration. Crucially, digital tools fail in isolation: patient engagement drops to 20% without supervision but exceeds 85% within a structured "clinician-in-the-loop" model, proving human clinical oversight remains essential for successful digital transformation.
  • Ahmad Izuanuddin Ismail Chairperson Malaysia
    Pang Yong Kek Chairperson Malaysia
Ballroom 1, Lower Ground Floor
15:00
16:00

21 November 2026, Saturday

22 November 2026, Sunday

Time Session
09:00
10:30
Pang Yong Kek Chairperson Malaysia
Ballroom 3, Lower Ground Floor
12:00
13:00
Irfhan Ali Hyder Ali Chairperson Malaysia
Justin Yu Kuan Tan Chairperson Malaysia
  • Pang Yong Kek Speaker Malaysia
    S34 - Haematological Disorder and Lungs By Yong Kek, Pang Following allogeneic haematopoietic stem cell transplantation (alloHSCT), pulmonary graft-versus-host disease (pGVHD) represents a serious complication driven by alloreactive donor immune cells, conditioning therapies, and infections. Acute manifestations present within 100 days primarily as pneumonia or bronchitis, whereas chronic pGVHD manifests beyond 100 days as bronchiolitis obliterans syndrome (BOS), interstitial lung disease (ILD), or rare vascular complications. Chronic pGVHD has an estimated cumulative incidence of ~20% within two years post-transplant, with BOS accounting for 56.4% and ILD for 30.8% of non-infectious complications. Because clinical onset is often indolent—and many patients are identified only after 40% to 50% of lung function is lost—early detection through structured surveillance is essential to prevent progressive, irreversible injury. Surveillance protocols recommend baseline and routine spirometry at 3 months, 6 months, and annually for 2 years post-transplant, with accelerated testing after acute flares or immunosuppression tapering. Patients with chronic pGVHD warrant spirometry at least every 6 months and annual full pulmonary function testing. Complementary assessments, including high-resolution CT (HRCT), 6-minute walk tests, and multidisciplinary reviews, are critical to exclude alternative pathologies and guide therapy.
  • Yet Hong Khor Speaker Australia
    Connective tissue diseases (CTDs) are increasingly prevalent, with lung involvement being common, which contributes to substantial morbidity and mortality. Lung involvement in CTD encompasses a broad spectrum of manifestations affecting the airways, lung parenchyma, pleura, pulmonary vasculature and respiratory muscles. Interstitial lung disease (ILD) represents one of the most frequent and clinically significant manifestations. Importantly, lung involvement may precede extra-pulmonary manifestations of CTD, creating diagnostic challenges for respiratory physicians. This presentation will provide a practical overview of the relationship between CTD and lung disease, with a particular focus on CTD-associated ILD. Management principles will also be explored, including multidisciplinary care models and the importance of tailoring treatment according to disease stage, underlying inflammatory and fibrotic mechanisms, and treatment goals. Bronchiolar disease and treatment-related pulmonary complications in CTD will be highlighted. The discussion aims to equip clinicians with practical strategies for the diagnosis and management of CTD-related lung disease in clinical practice.
  • Lalitha Pereirasamy Speaker Malaysia
    COPD and cardiovascular disease (CVD) frequently coexist and amplify each other, yet are usually managed separately. They share risk factors such as smoking, ageing and air pollution. Around half of COPD deaths are cardiovascular, and 7–30% of patients with acute myocardial infarction (AMI) have COPD. This presentation brings together recent reviews, a 24-study systematic review, and key cohort and trial data on the mechanisms linking COPD and CVD. It focuses on systemic inflammation and shared biomarkers. COPD confers a risk of major adverse cardiovascular events comparable to diabetes (adjusted HR 1.50 vs 1.41). It nearly triples heart failure risk, with the greatest excess in younger patients. The continuum begins early: low or declining FEV₁, even within normal limits, predicts heart failure, atrial fibrillation and stroke. Five bridges link the organs: systemic inflammation, hypoxaemia, pulmonary vascular remodelling, hyperinflation and autonomic dysfunction. Lung injury activates NF-κB and the NLRP3 inflammasome. IL-1β, IL-6, IL-8 and TNF-α then spill into the circulation, driving endothelial dysfunction, platelet activation and plaque instability. Exacerbations act as a “second hit”: cardiovascular event risk rises 22-fold during severe exacerbations, and AMI risk is eightfold in the first three days. IL-1 blockade is a promising shared target but remains untested in patients with both conditions. Conclusion :NT-proBNP, troponin, coronary artery calcium on chest CT and spirometry are ready for routine use. CRP, fibrinogen, neutrophil-to-lymphocyte ratio and heart rate variability are useful adjuncts. Every exacerbation should be treated as a cardiovascular risk window, with integrated pulmonology–cardiology care.
  • Q&A
Ballroom 2, Lower Ground Floor